Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Legend Biotech (LEGN) Payables (2019 - 2024)

Historic Payables for Legend Biotech (LEGN) over the last 7 years, with Q3 2025 value amounting to $102.5 million.

  • Legend Biotech's Payables rose 28078.87% to $102.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $102.5 million, marking a year-over-year increase of 28078.87%. This contributed to the annual value of $38.6 million for FY2024, which is 2589.79% up from last year.
  • According to the latest figures from Q3 2025, Legend Biotech's Payables is $102.5 million, which was up 28078.87% from $75.4 million recorded in Q2 2025.
  • In the past 5 years, Legend Biotech's Payables registered a high of $102.5 million during Q3 2025, and its lowest value of $7.0 million during Q4 2021.
  • Moreover, its 5-year median value for Payables was $31.8 million (2022), whereas its average is $37.8 million.
  • Its Payables has fluctuated over the past 5 years, first soared by 36703.11% in 2022, then tumbled by 680.39% in 2023.
  • Quarter analysis of 5 years shows Legend Biotech's Payables stood at $7.0 million in 2021, then surged by 367.03% to $32.9 million in 2022, then fell by 6.8% to $30.7 million in 2023, then increased by 25.9% to $38.6 million in 2024, then surged by 165.47% to $102.5 million in 2025.
  • Its last three reported values are $102.5 million in Q3 2025, $75.4 million for Q2 2025, and $58.1 million during Q1 2025.